Demographic and clinical characteristics of psoriatic arthritis (PsA) patients.
| Characteristics | PsA, n = 50 |
|---|---|
| Age, yrs | 58.42 (± 8.33) |
| Males | 27 (54) |
| Joint-related | |
| Age at PsA onset, yrs | 37.14 (± 12.14) |
| PsA duration, yrs | 18.84 (± 7.83) |
| TJC max, 0–68 | 12.75 (± 7.05) |
| SJC max, 0–68 | 9.07 (± 4.84) |
| CPDAI, 0–15 | 3.97 (± 2.02) |
| CRP, mg/l | 4.49 (± 8.48) |
| ESR max, mm/h | 25.02 (± 21.52) |
| CRP max, mg/l | 21.42 (± 23.97) |
| No. deformed joints, 0–68 | 7.3 (± 9.2) |
| Dactylitis | 24 (48) |
| Enthesitis | 21 (42) |
| Sacroiliitis | 14 (28) |
| Deformed joints | 34 (68) |
| Fused joints | 18 (36) |
| Erosion | 32 (64) |
| Osteolysis | 10 (20) |
| Axial involvement | 23 (46) |
| Mutilans | 9 (18) |
| Skin-related | |
| Age at onset of psoriasis, yrs | 32.5 (± 13.98) |
| PASI, 0–72 | 2.2 (± 3.13) |
| PASI max ever, 0–72 | 4.64 (± 4.69) |
| BSA max ever, 0–100% | 8.7 (± 11.06) |
| DLQI, 0–30 | 2.8 (± 4.09) |
| Nail involvement | 42 (84) |
| Patient-reported data | |
| Alcohol, unit/week | 9.12 (± 8.92) |
| HAQ, 0–3 | 0.612 (± 0.45) |
| BASDAI, 0–10 | 3.1 (± 1.8) |
| BASFI, 0–10 | 3.21 (± 2.37) |
| ASQoL, 0–18 | 5.71 (± 4.68) |
| Current medications | |
| DMARD | 31 (62) |
| Biologic | 33 (66) |
| Combination | 15 (30) |
Data are n (%) or mean ± SD. TJC: tender joint count; SJC: swollen joint count; CPDAI: Composite Psoriatic Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PASI: Psoriasis Area and Severity Index; BSA: body surface area; DLQI: Dermatology Life Quality Index; HAQ: Health Assessment Questionnaire; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: Ankylosing Spondylitis Quality of Life score; DMARD: disease-modifying antirheumatic drug.